InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 198681

Tuesday, 11/17/2015 11:37:01 PM

Tuesday, November 17, 2015 11:37:01 PM

Post# of 346340

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL : Video =48:53 in length ....




You got PPHM ? : )

You know about Dmitry Gabrilovich?

Follow this chain of posts all the way back to the day Peregrine Pharmaceuticals brought Dmitry on board... back on Dec 10, 2013 and you will see why MDSC's are relevant and all interconnected to flipped PS.

I don't know what the rush is though.... don't we have till 2016 or 2017 ? : )



Dmitry I. Gabrilovich: Regulation of Immune Response in Cancer by Myeloid Cells

19 November

Speaker: Dmitry I. Gabrilovich, Christopher M. Davis See Professor, The Wistar Institute, Philadelphia, USA.

Host: Anna Martner anna.martner@microbio.gu.se

Two open lectures are Offered on November 19 in collaboration between Sahlgrenska Cancer Center, Biocare and the Sahlgrenska Academy Seminars. During the lunch break between the two lectures, a light lunch is served outside the

Time
12: 15-13: 15

Place
Lecture Hall Arvid Carlsson, Academicum, Medicinaregatan 3

https://translate.google.com/translate?hl=en&sl=sv&u=www.akademiliv.se/seminarier/&prev=search


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News